News

COVID-19 update: Genoskin to maintain US production activity during pandemic. In light of the latest updates on the COVID-19 pandemic, Genoskin’s top priority remains both employees and collaborators’ safety. Thanks to the ability to rely on skin expertise and model production in the US location (Salem, MA), Genoskin continues to provide partners with the available support needed in reliably and quickly

Read more

Genoskin COVID-19 research preferred access program On Friday, March 13th 2020, Genoskin launched a preferred access program for all research teams actively developing therapeutic and vaccine technologies for the COVID-19 pandemic. The World Health Organization (WHO) officially declared on March 11th, the outbreak of COVID-19 a pandemic. The disease caused by SARS-CoV-2 has spread globally. Over 130,000 individuals are affected so

Read more

6 steps to get your new product approved by FDA In the USA, any new drug or biologic needs a stamp of approval from the Food and Drug Administration (FDA) before going to the market. The development of a new drug and the approval process can be long and difficult. To make it easier for you, we have gathered belowRead more

Join us at SOT2020! Genoskin team is getting ready for the SOT2020 Annual Meeting and ToxExpo next month in Anaheim, CA. Our skin experts, Yolaine Robitaille, Field Application Director, and Eric Merle, CCO are excited to meet you at booth #1200. Take the opportunity to come by and learn more about how our ex vivo human skin assays predict injectionRead more

New published data generated with Genoskin human skin assays Genoskin assays are designed for fast and reliable studies with reproducible results. As we aim to empower research teams with the best technology to generate better human data, we are proud to discover new published data involving our skin assays.  The potential to evaluate nanoparticles toxicity In NanoImpact, a research teamRead more

Genoskin reinforces R&D capabilities Genoskin Research & Development offers new services to portfolio available to partners with the addition of new equipment. Genoskin's R&D recently added a Meso Scale QuickPlex SQ120 for high-performance electroluminescence immunoassays. This new instrument will enable our teams to detect the presence of biomarkers down to femtoscale concentrations. Genoskin also added a best-in-class solar simulator (Solar Light) capable ofRead more